Evaluation of REMS Outcomes to be Baked Into Applications Says Guidance

NDAs, ANDAs and BLAs need to incorporate risk evaluation and mitigation strategies (REMS) with clear goals, objectives, and strategies that align with the intended outcomes not only for the design of the REMS but also for future modification, a new FDA draft guidance says.
Source: Drug Industry Daily